INTRODUCTION

Mechanical ventilation (MV) is a life-saving treatment for patients suffering from acute respiratory failure, but it may also lead to patient’s reliance on ventilators because of a resultant and rapid decline of diaphragm muscle endurance and strength, which is termed ventilator-induced diaphragmatic dysfunction (VIDD).1-3 Numerous studies have determined that VIDD could raise weaning failure rate, intensive care unit (ICU) stay and medical expenditures.2,3 However, the mechanisms of VIDD, presumably encompassing a multistep
process that involves oxidative loads, muscle atrophy (arising from calpain, caspase-3, the autophagy-lysosomal pathway [ALP] and ubiquitin-proteasome system [UPS] activation), structural damage and muscle fibre remodelling, have not been fully explored.\(^4\)\(^6\) Therefore, a detailed understanding of the precise mechanisms underlying VIDD is critical for the development of potential strategies to reduce the prolonged use of MV and thus ICU mortality.

Sepsis is a major risk factor for ICU patients developing diaphragm dysfunction.\(^2\)\(^3\)\(^7\) During the progress of sepsis, deleterious host response to infectious constituents, such as lipopolysaccharide (LPS), may induce an inflammatory cascade and cause ventilator-associated pneumonia (VAP), subsequently leading to multiple organ failure.\(^5\)\(^8\)\(^10\) Animal studies have demonstrated that infection is a principal cause of abnormal diaphragm activities.\(^8\)\(^11\) Sepsis-mediated diaphragmatic weakness and VIDD involve common molecular pathways, namely excessive oxidative loads and mitochondrial abnormalities within the injured diaphragm myofibrils, suggesting that sepsis may be an accessory contributor to VIDD.\(^5\)\(^6\)\(^8\)\(^10\) In an acute lung injury (ALI), reactive oxygen species (ROS) are the major oxidants in the diaphragm and can be produced in mitochondria, sarcoplasmic reticula, sarcolemma, transverse tubes and cytosol within 6 hours of MV.\(^12\)\(^13\) Furthermore, sepsis and MV-induced oxidative stress may deteriorate diaphragm contractility and are critical contributors to proteolytic pathway activation.\(^14\)\(^16\) The primary proteases in the skeletal muscle consist of (1) UPS, (2) calcium-related proteases and (3) lysosomal enzymes.\(^10\)\(^17\) The up-regulation of muscle-specific ubiquitin E3 ligases F-box protein atrogin-1 and muscle RING-finger proteins-1 (MuRF-1) is crucial for the proteolysis of monomeric myofibrillar proteins in the diaphragms of animals and patients using MV.\(^16\)\(^18\) Increased autophagosome formation also occurs in MV-augmented diaphragmatic weakness, as reflected in an elevation of autophagic biomarker microtubule-related protein light chain (LC) 3.\(^19\)\(^21\) Mitochondria are a principal source of diaphragmatic ROS and act as a pivotal upstream regulator that induces the molecular pathways engendering diaphragm muscle atrophy during endotoxaemia or MV.\(^22\)\(^23\) In addition, myonuclear apoptosis can also be accelerated by mitochondrial ROS, elevated cellular calcium levels and sarcoplasmic reticulum stress-induced activation of calpain and caspase-3.\(^20\)\(^24\) Furthermore, sepsis and MV-induced oxidative stress may up-regulate the production of inflammatory mediators, including high-mobility group box 1 (HMGB1), interleukin 6 (IL-6) and plasminogen activator inhibitor-1 (PAI-1).\(^9\)\(^15\)\(^25\)\(^29\) and subsequently impair diaphragm activities.

Rodent studies of endotoxaemia have revealed that toll-like receptor 4 (TLR4) modulates diaphragm injury by activating the nuclear factor-κB (NF-κB) pathway.\(^11\)\(^30\) In our previous mouse study investigating sepsis, the reduced ALP and mitigated mitochondrial ultrastructural changes were observed by inhibiting TLR4/NF-κB signalling through genetic manipulation of TLR4 using homozygous knockout.\(^31\) TLR4 is the most renowned receptor of the TLR family and is crucial for the recognition of the damage-associated molecular pattern (DAMP), including extracellular matrix components, HMGB1 and LPS.\(^30\)\(^32\) Although inhibition of TLR4 could be an effective therapeutic strategy for VIDD, in light of the potential risk of increased infectious complications using this approach, targeting endogenous TLR4 ligands such as HMGB1 could be more prudent. Related studies have demonstrated that the expression levels of HMGB1 are associated with diaphragmatic dysfunction in caecal ligation and puncture in animals and that the administration of anti-HMGB1 antibodies can effectively attenuate sepsis-induced diaphragm dysfunction in septic rats.\(^26\)\(^26\) Several related studies have demonstrated that ethyl pyruvate, a potent free radical scavenger, can inhibit HMGB1 production and improve the survival of critically ill patients.\(^33\)\(^34\) Nevertheless, the use of ethyl pyruvate for the management of VIDD is still unexplored.

Murine endotoxaemia models have been employed to recapitulate human sepsis for nearly a century.\(^35\) In this study, we investigated that the impact of MV with or without LPS and related HMGB1 signalling contributes to VIDD using a murine model of endotoxaemia. We hypothesized that the administration of ethyl pyruvate or anti-HMGB1 antibody would diminish HMGB1 expression, diaphragmatic structural damage, generation of free radicals, proteolytic protein synthesis and mitochondrial dysfunction and restore muscle contractility in the diaphragm of mice with or without endotoxaemia exposed to MV.

## 2 | MATERIALS AND METHODS

### 2.1 | Experimental animals

Male C57BL/6 mice, weighing between 20 and 25 g, aged between 6 and 8 weeks, were obtained from the National Laboratory Animal Center (Taipei, Taiwan). The experiments were conducted in strict accordance with the National Institutes of Health Guidelines on the Use of Laboratory Animals. The Institutional Animal Care and Use Committee of Chang Gung Memorial Hospital approved the protocol (permit number: 2015101201). All surgery was performed under zoletil and xylazine anaesthesia, and all efforts were made to minimize suffering.

### 2.2 | Experimental groups

Animals were randomly distributed into six groups in each experiment: group 1, non-ventilated control wild-type mice with normal saline; group 2, non-ventilated control wild-type mice with LPS; group 3, tidal volume (VT) 10 mL/kg wild-type mice with normal saline; group 4, VT 10 mL/kg wild-type mice with LPS; group 5, VT 10 mL/kg wild-type mice after ethyl pyruvate (100 mg/kg) administration with LPS; group 6, VT 10 mL/kg wild-type mice after anti-HMGB1 antibody (100 mg/kg) with LPS; group 7, VT 10 mL/kg wild-type mice after ethyl pyruvate (50 mg/kg) administration with LPS; group 8, VT 10 mL/kg wild-type mice after anti-HMGB1 antibody (50 mg/kg) administration with LPS; group 9, VT 10 mL/kg wild-type mice after anti-HMGB1 isotype control antibody (100 mg/kg) administration with LPS. In groups 1-6, three mice underwent transmission electron microscopy (TEM) and specific force, and five mice
underwent measurement for immunohistochemistry assay, inflammatory cytokines, protein carbonyl groups, superoxide dismutase, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labelling (TUNEL) assay, and Western blots. In groups 7-9, five mice underwent measurement for HMGB1 and Western blots.

### 2.3 Ventilator protocol

We used our established murine model of VILI, as described previously. Briefly, a 20-gauge angiocatheter was inserted into the tracheotomy orifice of mice and general anaesthesia was maintained by regular intraperitoneal administration of zoletil 50 (5 mg/kg) and xylazine (5 mg/kg) at the beginning of the experiment and every 30 minutes. The depth of anaesthesia was monitored from heart rates, respiratory rates and limb reflexes induced by paw and tail pinches performed periodically. The mice were placed in a supine position on a heating blanket and then attached to a Harvard apparatus ventilator, model 55-7058 (Harvard Apparatus, Holliston, MA), set as tidal volume of 10 mL/kg at a rate of 100 breaths per min, for 8 hours while breathing room air with zero end-expiratory pressure. Schellekens et al and our previous work demonstrated that 8-hour MV in mice can induce increased cytokine expression, lysosomal autophagy and diaphragm atrophy. At the end of the study, heparinized blood was taken from the arterial line for analysis of arterial blood gas, and the mice were sacrificed. The non-ventilated control mice were anaesthetized and sacrificed immediately.

### 2.4 LPS and pharmacological inhibitors

Mice were administrated intravenously with either 1 mg/kg of Salmonella typhosa LPS (Lot 81H4018; Sigma Chemical Co., St. Louis, MO) or an equivalent volume of normal saline via the internal jugular vein as a control. After 1 hour of spontaneous respiration to allow for developing a septic response, the mice were subjected to MV for 8 hours. Two doses of ethyl pyruvate (Sigma, St Louis, MO) were administered intraperitoneally. The first dose was administered 30 minutes before the mice were subjected to MV and the second dose was used after the mice were subjected to 4 hours of MV. 

Anti-HMGB1 antibody 100 mg/kg (chicken anti-pig HMGB1 polyclonal antibody, SHINO-TEST, Tokyo, Japan) or isotype control antibody (non-immune immunoglobulin G, SHINO-TEST, Tokyo, Japan) was administered intravenously 30 minutes before the start of MV. The doses of ethyl pyruvate and anti-HMGB1 were chosen on the basis of our and other studies that showed 100 mg/kg ethyl pyruvate or anti-HMGB1 had better effects on inhibiting HMGB1 activity.

### 2.5 Detection of cytokines in the bronchoalveolar lavage fluid

PAI-1, with a lower detection limit of 0.02 ng/mL, and HMGB1 (1 ng/mL) were detected in bronchoalveolar lavage (BAL) fluid using immunoassay kits containing primary polyclonal anti-mouse antibodies that were cross-reactive with rat and mouse PAI-1 and HMGB1 (PAI-1: Molecular Innovations, Inc, Southfield, MI; HMGB1: Shino-Test corporation, Kanagawa, Japan). Each sample was run in duplicate, according to the manufacturer’s instructions.

### 2.6 Immunoblot analysis

The diaphragms were homogenized in 1 mL of lysis buffer (20 mmol/L HEPES pH 7.4), 1% Triton X-100, 10% glycerol, 2 mmol/L ethylene glycol-bis (β-aminoethyl ether)-N,N,N',N'-tetraacetic acid, 50 μmol/L β-glycerophosphate, 1 mmol/L sodium orthovanadate, 1 mmol/L dithioreitol, 400 μmol/L aprotinin and 400 μmol/L phenylmethylsulphonyl fluoride), transferred to Eppendorf tubes and placed on ice for 15 minutes. Tubes were centrifuged at 15 350g for 10 minutes at 4°C and supernatant was flash-frozen. The total protein concentration was detected by Bradford protein assay kit (Thermo Fisher Scientific Inc, Waltham, MA). Crude cell lysates associated with the total protein content were matched for protein concentration (30 μg per well for caspase-3 and LC3-II; 60 μg per well for calpain, atrogin-1 and MuRF-1), resolved on a 10% bis-acrylamide gel and electrotransferred to Immobilon-P membranes (Millipore Corp., Bedford, MA). For the assay of calpain, caspase-3, atrogin-1, MuRF-1, LC3-II and glyceraldehyde-phosphate dehydrogenase, Western blot analyses were analysed with respective antibodies (New England BioLabs, Beverly, MA and Santa Cruz Biotechnology, Santa Cruz, CA). Blots were developed by enhanced chemiluminescencescence (NEN Life Science Products, Boston, MA).

### 2.7 Immunohistochemistry

The diaphragms were paraffin embedded, sliced at 4 μm, deparaffinized, antigen unmasked in 10 mmol/L sodium citrate (pH 6.0), incubated with rabbit HMGB1 primary antibody (1:100; Santa Cruz Biotechnology, Santa Cruz, CA) and biotinylated goat anti-rabbit secondary antibody (1:100) according to the manufacturer’s instruction for an immunohistochemical kit (Santa Cruz Biotechnology, Santa Cruz, CA). The specimens were further conjugated with horseradish peroxidase-streptavidin complex, detected with a diaminobenzidine (DAB) substrate mixture and counterstained by haematoxylin. A dark-brown DAB signal, identified by arrows, indicated positive staining of HMGB1 of muscle fibres, whereas shades of light blue signified non-reactive cells.

### 2.8 Real-time polymerase chain reaction

For isolating total RNA, the lung tissues were homogenized in TRIzol reagents (Invitrogen Corporation, Carlsbad, CA), according to the manufacturer’s instructions. Total RNA (1 μg) was reverse transcribed using a GeneAmp polymerase chain reaction (PCR) system 9600 (PerkinElmer, Life Sciences, Inc, Boston, MA), as previously described. The following primers were used for real-time polymerase chain reaction: HMGB1, forward primer 5'-TGGCAAAAGCTGACATGCTGCT-3' and reverse primer 5'-GGATGCTCGCCTTTGATTTTGG-3' and GAPDH as internal control, forward primer 5'-GGACCGAGCCCACCTAACA-3' and reverse primer 5'-ACATACTCAGCACCAGGCTC-3' (Protech
All quantitative PCR reactions using SYBR Master Mix were performed on a CFX96 Touch Real-Time PCR Detection system (Bio-Rad Laboratories, Inc, Hercules, CA). All PCR reactions were performed in duplicate and heated to 95°C for 5 minutes followed by 40 cycles of denaturation at 95°C for 10 seconds, and annealing at 55°C for 30 seconds. The relative gene expression was calculated using $2^{-\Delta\Delta CT}$ method and the standard curves (cycle threshold values vs template concentration) were prepared for each target gene and for the internal control (GAPDH) in each sample. The specific gene’s cycle threshold (Ct) values were normalized to the GAPDH and compared with the non-ventilated control group with LPS that was assigned a value of 1 to calculate the relative fold change in expression.

2.9 | Statistical evaluation
The Western blots were quantitated using a National Institutes of Health (NIH) image analyser Image J 1.27z (National Institutes of Health, Bethesda, MD).
Health, Bethesda, MD) and presented as arbitrary units. Values were expressed as the mean ± SD from at least five separate experiments. The data of protein oxidation, superoxide dismutase, specific force, histopathologic assay and oxygenation were analysed using Statview 5.0 (Abacus Concepts, Cary, NC; SAS Institute). All results of real-time PCR and Western blots were normalized to the non-ventilated control wild-type mice with LPS. ANOVA was used to assess the statistical significance of the differences, followed by multiple comparisons with a Scheffe’s test, and a $P < 0.05$ was considered statistically significant. We have performed the Shapiro-Wilk normality test and verify that all data are parametric ($P > 0.05$). Additional details, including measurement of diaphragm force-frequency relationships, immunoblot analysis, immunohistochemistry, mitochondrial isolation, measurement of diaphragmatic oxidative stress and antioxidant enzyme expression, TEM and TUNEL assay were performed as previously described.\textsuperscript{9,31}

3 | RESULTS

3.1 | Reduction of the effects of MV on endotoxin-enhanced VIDD, oxygen radicals and inflammatory cytokines using ethyl pyruvate

We employed MV (10 mL/kg) at room temperature for 8 hours to elicit VIDD in mice. The physiological conditions at the beginning and end of MV are listed in Table S1. Normovolemic status was sustained in the mice by monitoring their mean arterial pressure. The dose-dependent responses of ethyl pyruvate and anti-HMGB1 used

![Figure 2](image_url)

**FIGURE 2** Ethyl pyruvate abrogated endotoxin-augmented mechanical ventilation-induced oxidative stress, inflammatory cytokines, calpain, atrogin-1 and MuRF-1 expression in the diaphragm. (A) protein carbonyl groups (diaphragm), (B) SOD (diaphragm), (C) BAL fluid active PAI-1 and (D) BAL fluid HMGB1 were from the non-ventilated control mice and mice ventilated at a tidal volume of 10 mL/kg for 8 h with or without LPS administration ($n = 5$ per group). Western blots were performed using antibodies that recognize calpain (E), atrogin-1 (F), MuRF-1 (G) and GAPDH expression from the diaphragms of non-ventilated control mice and mice ventilated at a tidal volume of 10 mL/kg for 8 h with or without LPS administration ($n = 5$ per group). Arbitrary units were expressed as relative calpain, atrogin-1 and MuRF-1 activation ($n = 5$ per group). Ethyl pyruvate, 100 mg/kg, was given intraperitoneally 30 min before mechanical ventilation and 4 h after mechanical ventilation. $^*P < 0.05$ vs the non-ventilated control mice with LPS treatment; $^{\dag}P < 0.05$ vs all other groups. BAL, bronchoalveolar lavage; GAPDH, glyceraldehydes-phosphate dehydrogenase; HMGB1, high-mobility group box-1; MuRF-1, muscle ring finger-1; PAI-1, plasminogen activator inhibitor-1; SOD, sodium dismutase
in this study were described in supplementary data (Figure S1). TEM was performed to explore MV- and LPS-induced changes in the diaphragm ultrastructures. Compared with mice without endotoxaemia (normal saline only) subjected to V\textsubscript{T}, 10 mL/kg and the non-ventilated controls, mice with endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg exhibited higher disarrangements in diaphragmatic myofibrillar structures with larger lipid droplets, unclear A- and I-bands, tortured Z-bands and mitochondrial swelling (Figure 1A-D). The administration of ethyl pyruvate substantially attenuated damage to the diaphragmatic fibres (Figure 1E). To determine the effects of sepsis and MV on diaphragm contractile conditions, we measured diaphragm muscle-specific force generation. Decreased diaphragm contractilities were observed in mice with endotoxaemia subjected to MV compared with those without endotoxaemia subjected to MV and the non-ventilated control mice (Figure 1F). The administration of ethyl pyruvate substantially suppressed MV- and endotoxin-mediated increases in diaphragmatic weakness. Several studies have indicated the crucial roles of MV-induced imbalances among oxidative loads, antioxidant capacity and inflammatory cytokines in worsening VIDD.\textsuperscript{4,6} Increased levels of active PAI-1, HMGB1 and protein carbonyl groups and decreased production of superoxide dismutase were evident in mice with endotoxaemia subjected to MV compared to those without endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg and the non-ventilated control mice (Figure 2A-D). However, a reversal of these features occurred after the administration of ethyl pyruvate.

### 3.2 Suppression of the effects of MV on endotoxin-augmented calpain, atrogin-1 and MuRF-1 expression through the use of ethyl pyruvate

Western blot analyses were carried out to identify the effects of MV on the endotoxin-augmented UPS related to VIDD. Total calpain, atrogin-1 and MuRF-1 levels were higher in mice with endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg than in those without endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg and the non-ventilated control mice (Figure 2E-G). Administering ethyl pyruvate substantially alleviated the elevated expression levels of calpain, atrogin-1 and MuRF-1 caused by endotoxaemia and 10 mL/kg MV.

### 3.3 Inhibition of the effects of MV on endotoxin-exacerbated HMGB1 mRNA and HMGB1 protein expression through the use of ethyl pyruvate and anti-HMGB1 antibody

HMGB1 is an inflammatory cytokine and an intracellular regulator of transcription and its activation has been associated with diaphragm weakness in a sepsis model of rats.\textsuperscript{15,26,39} Real-time PCR was performed to measure the effects of MV on endotoxin-associated HMGB1 mRNA expression in the diaphragm (Figure 3A). The expression level of HMGB1 mRNA was up-regulated in mice with endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg compared to those without endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg and the non-ventilated control mice. The increase in HMGB1 mRNA expression after MV was substantially reduced by the administration of either ethyl pyruvate or anti-HMGB1 antibody (Figure 3A). Immunohistochemistry was employed to discern the effects of HMGB1 expression in endotoxin-mediated VIDD (Figure 3B). A substantial elevation in the number of diaphragm muscle fibres positively stained for HMGB1 was observed in mice with endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg compared to those without endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg and the non-ventilated control mice. The elevated HMGB1 expression levels after MV were substantially diminished after the administration of either ethyl pyruvate or anti-HMGB1 antibody (Figure 3B).

### 3.4 Reduction of the effects of MV on endotoxin-augmented VIDD by ethyl pyruvate and anti-HMGB1 antibody

To determine the role of HMGB1 activation in stretch-induced diaphragm injury, anti-HMGB1 antibody was employed to examine whether the improvements in diaphragm abnormalities caused by the administration of ethyl pyruvate was induced through HMGB1 expression. The effects of MV (elevation in oxidative stress; active PAI-1 and HMGB1 generation; expression levels of calpain, atrogin-1, and MuRF-1; diaphragm myofibrillar structures and contractilities as well as autophagosomes) in mice with endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg were substantially reduced by the use of an anti-HMGB1 antibody (P < 0.05; Figures 4 and 5A,B). Furthermore, Western blots were conducted to assess the effects of MV on endotoxin-augmented mitochondrial damage and ALS associated with VIDD. Down-regulated mitochondrial cytochrome C, a marker of mitochondrial structural integrity,\textsuperscript{9} and up-regulated LC3-II expression, an indicator of autophagy, \textsuperscript{24} were observed in mice with endotoxaemia subjected to MV, but not in those without endotoxaemia subjected to MV and the non-ventilated control mice (Figure 5C,D). However, amelioration of these injuries was observed after the administration of ethyl pyruvate or anti-HMGB1 antibody (P < 0.05; Figure 5C,D). Taken together, more extensive diaphragmatic damage in mice with endotoxaemia receiving MV compared to those without endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg (Figures 4 and 5) indicated the synergistic effects of LPS treatment.

### 3.5 Suppression of the effects of MV on endotoxin-enhanced expression of caspase-3 and diaphragm apoptosis by ethyl pyruvate and anti-HMGB1 antibody

Studies have demonstrated that caspase-3 is crucial to the intrinsic apoptotic pathway.\textsuperscript{20,31} Caspase-3 expression and TUNEL staining were used to identify the roles of the caspase-3 pathway and apoptosis of diaphragm myofibrils in endotoxin-related VIDD (Figure 6). A substantial up-regulation in caspase-3 expression and the emergence of TUNEL-positive apoptotic nuclei in the murine diaphragm occurred in mice with endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg, but not in those without endotoxaemia subjected to V\textsubscript{T}, 10 mL/kg.
and the non-ventilated control mice (Figure 6B,C). Specifically, the activation in caspase-3, as well as MV- and endotoxin-enhanced apoptosis, in the murine diaphragm was restored following the administration of ethyl pyruvate as well as anti-HMGB1 antibody. Collectively, our results suggest that endotoxin- and concurrent MV-mediated oxidative loads and the inflammatory reactions in the diaphragm were protected by the inhibition of the HMGB1 pathway (Figure 7).

4 | DISCUSSION

In clinical practice, MV is required to provide adequate ventilation and oxygenation in patients with sepsis and respiratory insufficiency. Infection can trigger substantial diaphragm dysfunction in animal and clinical human studies of sepsis. However, the use of MV can lead to the rapid development of diaphragm weakness and ventilator-induced lung injury (VILI) in humans. Recently, MV was determined to likely aggravate diaphragm injuries in a murine model of endotoxaemia. The combination of infection and ventilator-induced diaphragm disuse exacerbated the diaphragmatic force-generating contractility in mechanically ventilated patients. Diaphragm dysfunction is a critical determinant that negatively influences the clinical outcome of critically ill patients and typically accompanies prolonged MV exposure, and increases ventilator-associated complications, and mortality. Thus, potent pharmacological agents should be sought to effectively ameliorate the diaphragm dysfunction induced in such critical situations and facilitate the successful weaning of MV. In this study, we demonstrated that ethyl pyruvate can (a) mitigate oxidative stress and improve antioxidant ability, (b) decrease inflammatory cytokines HMGB1 and PAI-1, (c) ameliorate muscle proteolysis and apoptosis, (d) attenuate mitochondrial injury and autophagy and (e) restore the ultrastructural integrity and muscle contractility in a mouse model of VIDD with endotoxaemia. Moreover, we investigated the deleterious role of HMGB1 in mediation of the pathogenic mechanisms of diaphragm injury.

HMGB1, a non-histone chromosomal protein, is translocated to the cytosol from the nucleus and then released from cells under
stressful situations. Thus, HMGB1 acts as a catastrophic inflammatory cytokine passively released by damaged tissues or actively secreted from activated inflammatory cells during sepsis.\textsuperscript{26,40} Extracellular HMGB1 can be expressed as a DAMP by binding to TLR4, triggering inflammatory responses for host defence during early sepsis and producing cytokine cascades in later stages of sepsis.\textsuperscript{40} Furthermore, previous studies of ALI in mice and monocytes pretreated with HMGB1 demonstrated that HMGB1 triggered lung inflammation with neutrophil sequestration and releases of pro-inflammatory cytokines, including IL-1\textbeta, macrophage inflammatory protein-2 and tumour necrosis factor-\alpha.\textsuperscript{41,42} Elevated HMGB1 levels have been observed in the pulmonary epithelial lining fluid of septic patients.\textsuperscript{43} Moreover, HMGB1 was revealed to accelerate muscle fatigue, and is believed to be an early trigger of skeletal muscle dysfunction through binding to TLR4. HMGB1 is also believed to impair sarcoplasmic reticulum Ca\textsuperscript{2+} release in patients with myositis.\textsuperscript{30} High HMGB1 concentrations were observed to be associated with patients who required long-term MV use and those with VAP.\textsuperscript{44} Previous studies on VILI have determined that MV can up-regulate the production of HMGB1 and that HMGB1 is a pivotal mediator in the development of VILI.\textsuperscript{29,45} Furthermore, a moderate V\textsubscript{T} of MV can aggravate LPS-induced lung injury by up-regulating HMGB1.\textsuperscript{46} However, no studies have investigated the role of HMGB1 in VIDD and endotoxaemia, a critical situation simulating the clinical scenario. Previous related studies have demonstrated that HMGB1 expression in the diaphragm is associated with impaired diaphragm contractility and diaphragm dysfunction in septic animals with peritonitis.\textsuperscript{15,26,28} Our present study demonstrated that a moderate V\textsubscript{T} of ventilation can enhance the HMGB1 production from the diaphragm of LPS-challenged mice with endotoxaemia and worsen diaphragmatic injury, as evident in increased oxidative stress, inflammation, atrophy, apoptosis, mitochondrial injury and...
These deleterious effects were attenuated by using the anti-HMGB1 antibody. Although ROS and early cytokines are important to contribute to VIDD, and herein, we provide the evidence that using anti-HMGB1 antibody can elevate the SOD activity and suppress the oxidants, inflammatory cytokines and VIDD comparable to the beneficial effects of ethyl pyruvate in this model (Figures 3-6). In addition, we proved that MV induces diaphragmatic injury in a mouse model of endotoxaemia through activation of the TLR4/NF-κB signalling pathway. This inspired us to investigate the role of HMGB1, a pivotal ligand of the TLR4 receptor, and develop an effective agent to improve VIDD during endotoxaemia.

Ethyl pyruvate, a simple aliphatic ester, is derived from the endogenous metabolite of pyruvic acid. Ethyl pyruvate can function as both a potent ROS scavenger and anti-inflammatory agent through the up-regulation of haem oxygenase-1 or suppression of the NF-κB and p38 mitogen-activated protein kinase (MAPK)-mediated inflammatory responses. Ethyl pyruvate can also act as an HMGB1 inhibitor and ameliorate the systemic inflammation and organ dysfunction in animal models of endotoxaemia and sepsis. In addition, a proprietary formulation of ethyl pyruvate preserved the mitochondrial integrity by inhibiting the NLRP3 inflammasome in human acute monocytic leukaemia cell lines. In the present study, we

**FIGURE 5** Inhibition of endotoxin-augmented mechanical ventilation-induced diaphragmatic injury by ethyl pyruvate and anti-HMGB1 antibody. (A) Representative micrographs of the longitudinal sections of diaphragm (×40,000) were from the diaphragms of non-ventilated control mice and mice ventilated at a tidal volume of 10 mL/kg for 6 h with or without LPS administration (n = 3 per group). Mitochondrial swelling with coexisting vacuole formation, loss of cristae and autophagosomes containing heterogeneous cargo is identified by arrows. (B) Diaphragm muscle-specific force production was measured as described in Methods. (C) Western blots were performed using antibodies that recognize mitochondrial cytochrome C, LC3-II and GAPDH expression from the diaphragms of non-ventilated control mice and mice ventilated at a tidal volume of 10 mL/kg for 6 h with or without LPS administration (n = 5 per group). Arbitrary units were expressed as relative mitochondrial cytochrome C and LC3-II activation (n = 5 per group). Ethyl pyruvate, 100 mg/kg, was given intraperitoneally 30 min before mechanical ventilation and 4 h after mechanical ventilation. Anti-HMGB1 antibody, 100 mg/kg, was administered intravenously 30 min before the start of ventilation. *P < 0.05 vs the non-ventilated control mice with LPS treatment; †P < 0.05 vs all other groups. Scale bars represent 500 nm. LC3-II, light chain 3-II; Mito-Cyt C, mitochondrial cytochrome C.
demonstrated that ethyl pyruvate can ameliorate diaphragmatic injury through the reduction of oxidative stress, inflammation, proteolysis, apoptosis, autophagy and mitochondrial injury, all of which are achieved through the inhibition of HMGB1. Although Su et al showed that a single dose of ethyl pyruvate (100 mg/kg) decreased NF-κB and plasma cytokines in 3 h, but those inflammatory parameters were elevated in 9 hours in high-dose LPS (30 mg/kg)-challenged mice for survival test. In the subsequent study, ethyl pyruvate at different doses of 100 mg/kg or 50 mg/kg was proven to reduce the mortality from endotoxin-induced ALI and the permeability index in mice. Notably, the beneficial effects of 100 mg/kg ethyl pyruvate were superior compared to those of 50 mg/kg, which are consistent with our dose-response results (Figure S1).

Further investigation is necessary to explore other possible molecular mechanisms that involve HMGB1 and the advantageous effects of ethyl pyruvate in preventing patients with endotoxaemia from developing VIDD. Second, we utilized the anti-HMGB1 antibody in the study since HMGB1-/- mice die shortly after birth due to a defect in the transcriptional activation of the glucocorticoid receptor. However, Kim et al reported that intranasal delivery of HMGB1 siRNA provides the neuroprotection in the ischaemic brain mediated by target gene knockdown. Further alternative agents are expected to be researched in future studies.

By using an in vivo murine model of VIDD with endotoxaemia, we demonstrated that MV worsened LPS-challenged diaphragm
injury and dysfunction, as reflected in increased oxidative stress and higher levels of inflammatory cytokines HMGB1 and PAI-1; proteolytic proteins calpain, atrogin-1 and MuRF-1; apoptotic enzyme caspase-3; autophagic marker LC3-II expression; and more mitochondrial injury. This was also demonstrated through reduced antioxidant activity, mitochondrial cytochrome C levels and muscular force-generating capacity. The deleterious effects of MV on the diaphragm of mice with endotoxaemia can be alleviated by pharmacological inhibition with ethyl pyruvate, a HMGB1 inhibitor, or the use of anti-HMGB1 antibody, which block the HMGB1-mediated diaphragmatic injury and restore the ultrastructural integrity and functional contractility of the diaphragm. Understanding the beneficial mechanisms of ethyl pyruvate achieved through the regulation of HMGB1 may contribute to the development of novel biomarkers for monitoring diaphragmatic dysfunction during the use of MV and contribute to the growing knowledge of precise pathogenic mechanisms of combinatorial infection and MV involved in the development of diaphragmatic damage.

ACKNOWLEDGEMENTS

The study was supported by grants from the Ministry of Science and Technology (102-2314-B-182A-091-MY2 and 107-2314-B-182A-1431-MY3). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors thank Chang-Hung Tien, Laboratory Animal Center, the Microscope Core Laboratory, Chang Gung Memorial Hospital, Linkou, and Wallace Academic Editing, for their help with the experiment.

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interest.

AUTHOR’S CONTRIBUTION

LFL and YYL performed the experiments and wrote the manuscript. NHC, CHC, SWL, KCK, HCH and GJC designed the experiments and analysed the data.

ORCID

Li-Fu Li https://orcid.org/0000-0001-5819-7238

REFERENCES

1. Petrof BJ. Diaphragm weakness in the critically ill: basic mechanisms reveal therapeutic opportunities. Chest. 2018;154:1395-1403.
2. Demoule A, Molinari N, Jung B, et al. Patterns of diaphragm function in critically ill patients receiving prolonged mechanical ventilation: a prospective longitudinal study. Ann Intensive Care. 2016;6:75.
3. Jung B, Mouri PH, Mahul M, et al. Diaphragmatic dysfunction in patients with ICU-acquired weakness and its impact on extubation failure. Intensive Care Med. 2016;42:853-861.
4. Jaber S, Petrof BJ, Jung B, et al. Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am J Respir Crit Care Med. 2011;183:364-371.
5. Supinski GS, Callahan LA. Diaphragm weakness in mechanically ventilated critically ill patients. Crit Care. 2013;17:R120.
6. Tang H, Shrager JB. The signaling network resulting in ventilator-induced diaphragm dysfunction. Am J Respir Cell Mol Biol. 2018;59:417-427.

7. Demoule A, Jung B, Prodanovic H, et al. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact—a prospective study. Am J Respir Crit Care Med. 2013;188:212-219.

8. Maes K, Stamiris A, Thomas D, et al. Effects of controlled mechanical ventilation on sepsis-induced diaphragm dysfunction in rats. Crit Care Med. 2014;42:e772-e782.

9. Schellekens W-J, van Hees H, Vaneker M, et al. Toll-like receptor 4 signaling in ventilator-induced diaphragm atrophy. Anesthesia. 2012;117:329-338.

10. Dres M, Goligher EC, Heunks L, Brochard LJ. Critical illness-associated diaphragm weakness. Intensive Care Med. 2017;43:1441-1452.

11. Doyle A, Zhang G, Abdel Fattah EA, et al. Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 2011;25:99-110.

12. Zergeroglu MA, McKenzie MJ, Shanely RA, Van Gammeren D, et al. Reactive oxygen species are signalling molecules for skeletal muscle adaptation. Exp Physiol. 2010;95:1-9.

13. Smuder AJ, Hudson MB, Nelson WB, et al. Nuclear factor-kappaB signaling contributes to mechanical ventilation-induced diaphragm weakness. Crit Care Med. 2012;40:927-934.

14. Qiu YW, Chen D, Xu MY, et al. Beneficial effects of dantrolene on sepsis-induced diaphragmatic dysfunction are associated with downregulation of high-mobility group box 1 and calpain-caspase-3 proteolytic pathway. J Surg Res. 2016;200:637-647.

15. Files DC, D’Alessio FR, Johnston LF, et al. A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting. Am J Respir Crit Care Med. 2012;185:825-834.

16. Powers SK, Wiggs MP, Sollanek KJ, Smuder AJ. Ventilator-induced diaphragm dysfunction: cause and effect. Am J Physiol Regul Integr Comp Physiol. 2013;305:R464-R477.

17. Tang H, Lee M, Khuong A, Wright E, Shrager JB. Diaphragm muscle atrophy in the mouse after long-term mechanical ventilation. Muscle Nerve. 2013;48:272-278.

18. Azuelos I, Jung B, Picard M, et al. Relationship between autophagy and ventilator-induced diaphragmatic dysfunction. Anesthesiology. 2015;122:1349-1361.

19. Mofarrah M, Sigala I, Guo Y, et al. Autophagy and skeletal muscles in sepsis. PLoS ONE. 2012;7:e47265.

20. Smuder AJ, Sollanek KJ, Nelson WB, et al. Crossstalk between autophagy and oxidative stress regulates proteolysis in the diaphragm during mechanical ventilation. Free Radic Biol Med. 2018;115:179-190.

21. Picard M, Azuelos I, Jung B, et al. Mechanical ventilation triggers abnormal mitochondrial dynamics and morphology in the diaphragm. J Appl Physiol. 1985;115(18):1161-1171.

22. Kavazis AN, Talbert EE, Smuder AJ, Hudson MB, Nelson WB, Powers SK. Mechanical ventilation induces diaphragmatic mitochondrial dysfunction and increased oxidant production. Free Radic Biol Med. 2009;46:842-850.

23. Tang H, Lee M, Budak MT, et al. Intrinsic apoptosis in mechanically ventilated human diaphragm: linkage to a novel Fos/FoxO1/Stat3-Bim axis. FASEB J. 2011;25:2921-2936.

24. Okazaki T, Liang F, Li T, et al. Muscle-specific inhibition of the classical nuclear factor-kappaB pathway is protective against diaphragmatic weakness in murine endotoxemia. Crit Care Med. 2014;42:e501-e509.

25. Jiang J, Yang B, Han G, Yang M, Li S. Early administration of cisatracurium attenuates sepsis-induced diaphragm dysfunction in rats. Inflammation. 2015;38:305-311.

26. Park EJ, Kim YM, Kim HJ, Chang KC. Degradation of histone deacetylase 4 via the TLR4/JAK/STAT1 signaling pathway promotes the acetylation of high mobility group box 1 (HMGB1) in lipopolysaccharide-activated macrophages. FEBs Open Bio. 2018;8:1119-1126.

27. Li LF, Kao K-C, Yang C-T, Huang C-C, Liu Y-Y. Ethyl pyruvate reduces ventilation-induced neutrophil infiltration and oxidative stress. Exp Biol Med (Maywood). 2012;237:720-727.

28. Zong M, Bruton JD, Grundtman C, et al. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis. 2013;72:1390-1399.

29. Li LF, Liu YY, Chen NH, et al. Attenuation of ventilation-induced diaphragm dysfunction through toll-like receptor 4 and nuclear factor-kappaB in a murine endotoxemia model. Lab Invest. 2018;98:1170-1183.

30. Grundtman C, Bruton J, Yamada T, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J. 2010;24:570-578.

31. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic infection. Proc Natl Acad Sci USA. 2002;99:12351-12356.

32. Shang G-H, Lin D-J, Xiao W, et al. Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model. Respir Res. 2009;10:91.

33. Lewis AJ, Seymour CW, Rosengart MR. Current murine models of sepsis. Surg Infect (Larchmt). 2016;17:385-393.

34. Liu YY, Lee C-H, Dedaj R, et al. High-molecular-weight hyaluronan- a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Crit Care. 2008;12:R102.

35. Park JS, Arcaroli J, Yum H-K, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 2003;284:C870-C879.

36. Yu Y, Yu Y, Liu M, et al. Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-kB pathway. Springer Plus. 2016;5:215.

37. Su X, Wang H, Zhao J, et al. Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-kappaB pathway after traumatic brain injury in the rat. Mediators Inflamm. 2011;2011:807142.

38. Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine. 2010;51:119-126.

39. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565-570.

40. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. Cutting edge: HMG-1 as a mediator of acute lung inflammation. J Immunol. 2000;165:2950-2954.

41. Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170:1310-1316.

42. van Zoelen M, Ishizaka A, Woltius EK, Choi G, van der Poll T, Schultz MJ. Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia. Shock. 2008;29:441-445.

43. Ogawa EN, Ishizaka A, Tasaka S, et al. Contribution of high-mobility group box 1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med. 2006;174:400-407.
46. Ding N, Wang F, Xiao H, Xu L, She S. Mechanical ventilation enhances HMGB1 expression in an LPS-induced lung injury model. PLoS ONE. 2013;8:e74633.

47. Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol. 2008;21:160-167.

48. Yang R, Gallo DJ, Baust JJ, et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol. 2002;283:G212-G221.

49. Jang HJ, Kim YM, Tsoyer I, et al. Ethyl pyruvate induces heme oxygenase-1 through p38 mitogen-activated protein kinase activation by depletion of glutathione in RAW 264.7 cells and improves survival in septic animals. Antioxid Redox Signal. 2012;17:878-889.

50. Miyaji T, Hu X, Yuen P, et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int. 2003;64:1620-1631.

51. Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. Front Physiol. 2015;6:93.

52. Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal. 2011;14:1315-1335.

53. Kim YM, Park EJ, Kim JH, Park SW, Kim HJ, Chang KC. Ethyl pyruvate inhibits the acetylation and release of HMGB1 via effects on SIRT1/STAT signaling in LPS-activated RAW264.7 cells and peritoneal macrophages. Int Immunopharmacol. 2016;41:98-105.

54. Li S, Liang F, Kwan K, et al. Identification of ethyl pyruvate as a NLRP3 inflammasome inhibitor that preserves mitochondrial integrity. Mol Med. 2018;24:8.

55. Su J, Li X, Cui X, et al. Ethyl pyruvate decreased early nuclear factor-kappaB levels but worsened survival in lipopolysaccharide-challenged mice. Crit Care Med. 2008;36:1059-1067.

56. Jo YH, Kwon WY, Lee JH, et al. The effect of ethyl pyruvate on dapsone-induced methemoglobinemia in rats. Clin Toxicol (Phila). 2008;46:811-814.

57. Schroeder EL, Holcombe SJ, Cook VL, et al. Preliminary safety and biological efficacy studies of ethyl pyruvate in normal mature horses. Equine Vet J. 2011;43:341-347.

58. Bennett-Guerrero E, Swaminathan M, Grigore AM, et al. A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2009;23:324-329.

59. Lu B, Antoine DJ, Kwan K, et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci USA. 2014;111:3068-3073.

60. Kim I-D, Shin J-H, Kim S-W, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther. 2012;20:829-839.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Liu Y-Y, Chen N-H, Chang C-H, et al. Ethyl pyruvate attenuates ventilation-induced diaphragm dysfunction through high-mobility group box 1 in a murine endotoxaemia model. J Cell Mol Med. 2019;23:5679-5691. [https://doi.org/10.1111/jcmm.14478]